Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy

p53-based cyclotherapy is proving to be a promising approach to palliate undesired effects of chemotherapy in patients with tumours carrying p53 mutations. For example, pre-treatment of cell cultures with Nutlin-3, a highly-selective inhibitor of the p53-mdm2 interaction, has been successfully used...

Descripción completa

Detalles Bibliográficos
Autores principales: Rao, Bhavya, van Leeuwen, Ingeborg M.M., Higgins, Maureen, Campbell, Johanna, Thompson, Alastair M, Lane, David P, Lain, Sonia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2010
Materias:
Research Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248124/
https://www.ncbi.nlm.nih.gov/pubmed/21317459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3248124/
https://www.ncbi.nlm.nih.gov/pubmed/21317459

Ejemplares similares